WB
H M R Mk
Endogenous
75
Rabbit
#O94776
9219
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Rat, Monkey
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro602 of human MTA2 protein. Antibodies are purified by peptide affinity chromatography.
Background
MTA2 is a component of the NuRD deacetylase complex, which is recruited by MBD3 and modulates the enzymatic activity of the histone deacetylase core (1,2). MTA2 is highly related to MTA1, but both proteins exist in biologically distinct complexes, with MTA2 being associated with complexes containing Sin3a and CHD4 (3) MTA2 has been shown to bind ERα and repress its activity and contributes to estradiol- and tamoxifen-resistant breast cancers (4). Indeed, the MTA proteins are critical regulators of many biological functions in both cancer and non-cancer settings (5,6). MTA2 upregulation has been reported in a multitude of cancers, including hepatocellular carcinomas, colorectal cancers, gastric cancers, and esophageal cancers (7-10). MTA2 has also been described in B cell development, where it interacts with Aiolos and Ikaros to control target genes (11).
- Zhang, Y. et al. (1999) Genes Dev 13, 1924-35.
- Saito, M. and Ishikawa, F. (2002) J Biol Chem 277, 35434-9.
- Yao, Y.L. and Yang, W.M. (2003) J Biol Chem 278, 42560-8.
- Cui, Y. et al. (2006) Mol Endocrinol 20, 2020-35.
- Sen, N. et al. (2014) Cancer Metastasis Rev 33, 869-77.
- Kumar, R. and Wang, R.A. (2016) Gene 582, 112-21.
- Shi, W. et al. (2015) Int J Clin Exp Pathol 8, 13083-9.
- Ding, W. et al. (2015) Int J Clin Exp Pathol 8, 7173-80.
- Zhou, C. et al. (2013) Mol Cancer 12, 102.
- Liu, Y.P. et al. (2012) Exp Ther Med 3, 745-749.
- Lu, X. et al. (2019) Cell Rep 28, 472-485.e5.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
